Z

Zymeworks

D
ZYME
USD
-0.15
(-0.8961%)
Market Open
15,342.00
Volume
-1.72
EPS
-
Div Yield
-11.120000
P/E
1,185,070,465.20
Market Cap
Today
-0.3584%
1 Week
21.663%
1 Month
33.654%
6 Months
83.095%
12 Months
126.323%
Year To Date
60.385%
All Time
0%

Title:
Zymeworks

Sector:
Healthcare
Industry:
Biotechnology
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Do you need help or have a question?